Genentech's Vabysmo Slowly Chips Away at Competition in the Neovascular (Wet) AMD Market While Regeneron's Eylea Holds its Ground (For Now), According to New Spherix Report
/PRNewswire/ -- Since the FDA approval in January this year, ophthalmologists have been very optimistic about their intended use of Genentech's Vabysmo...
Source: prnewswire.com